KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Accumulated Expenses (2018 - 2025)

Adaptive Biotechnologies' Accumulated Expenses history spans 8 years, with the latest figure at $214000.0 for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 97.38% year-over-year to $214000.0; the TTM value through Dec 2025 reached $214000.0, down 97.38%, while the annual FY2025 figure was $214000.0, 97.38% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $214000.0 at Adaptive Biotechnologies, down from $7.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $15.6 million in Q4 2021 and bottomed at $154000.0 in Q4 2023.
  • The 5-year median for Accumulated Expenses is $8.0 million (2024), against an average of $8.6 million.
  • The largest annual shift saw Accumulated Expenses soared 17089.01% in 2021 before it plummeted 98.76% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $15.6 million in 2021, then fell by 20.57% to $12.4 million in 2022, then tumbled by 98.76% to $154000.0 in 2023, then surged by 5196.75% to $8.2 million in 2024, then tumbled by 97.38% to $214000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Accumulated Expenses are $214000.0 (Q4 2025), $7.2 million (Q3 2025), and $7.2 million (Q2 2025).